Patents by Inventor Hannes Lengauer

Hannes Lengauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200262792
    Abstract: The present invention relates to a co-crystal of roxadustat with L-proline and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said roxadustat L-proline co-crystal, at least one pharmaceutically acceptable excipient and optionally at least one photostabilizing agent. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).
    Type: Application
    Filed: July 11, 2018
    Publication date: August 20, 2020
    Applicant: Sandoz AG
    Inventors: Hannes Lengauer, Arthur Pichler, Renate Margreiter, Thomas Gelbrich
  • Publication number: 20200199070
    Abstract: The invention relates to crystalline eravacycline bis-hydrochloride and to a process for its preparation. Furthermore, the invention relates to the use of crystalline eravacycline bis-hydrochloride for the preparation of pharmaceutical compositions. The invention further relates to pharmaceutical compositions comprising an effective amount of crystalline eravacycline bis-hydrochloride. The pharmaceutical compositions of the present invention can be used as medicaments, in particular for treatment and/or prevention of bacterial infections e.g. caused by Gram negative pathogens or Gram positive pathogens, in particular caused by multidrug resistant Gram negative pathogens. The pharmaceutical compositions of the present invention can thus be used as medicaments for e.g.
    Type: Application
    Filed: January 20, 2017
    Publication date: June 25, 2020
    Applicant: Sandoz AG
    Inventor: Hannes Lengauer
  • Patent number: 10501450
    Abstract: The present invention relates to a brexpiprazole dihydrate crystalline form having a particle size distribution of d50 of at most 10 ?m and less than 5% w/w of brexpiprazole anhydrate. The present invention also relates to a process for preparing this brexpiprazole dihydrate crystalline form and to pharmaceutical compositions thereof. The present invention also relates to a process for determining the absence of brexpiprazole anhydrate in this brexpiprazole dihydrate crystalline form. This brexpiprazole dihydrate crystalline form is used for the preparation of pharmaceutical compositions having delayed release properties upon intramuscular injection.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: December 10, 2019
    Assignee: Hexal AG
    Inventors: Max Born, Christoph Langes, Hannes Lengauer
  • Publication number: 20190185507
    Abstract: The present invention relates to novel compounds for the treatment of Hepatitis C.
    Type: Application
    Filed: August 17, 2017
    Publication date: June 20, 2019
    Applicant: Sandoz AG
    Inventors: George Moore, Desiree Strych, Michael Papp, Olga Schoene, Thorsten Wilhelm, Hannes Lengauer
  • Patent number: 10265326
    Abstract: The present invention relates to crystalline form C of avibactam sodium and to a process for its preparation. The invention also concerns a pharmaceutical composition comprising form C and one or more antibacterial agents, wherein at least one antibacterial agent is a beta-lactam antibiotic. The pharmaceutical composition of the present invention can be used as medicament, in particular for treatment and/or prevention of bacterial infections.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: April 23, 2019
    Assignee: Sandoz AG
    Inventors: Andreas Hotter, Verena Adamer, Hannes Lengauer
  • Publication number: 20190047994
    Abstract: The present invention relates to a brexpiprazole dihydrate crystalline form having a particle size distribution of d50 of at most 10 ?m and less than 5% w/w of brexpiprazole anhydrate. The present invention also relates to a process for preparing this brexpiprazole dihydrate crystalline form and to pharmaceutical compositions thereof. The present invention also relates to a process for determining the absence of brexpiprazole anhydrate in this brexpiprazole dihydrate crystalline form. This brexpiprazole dihydrate crystalline form is used for the preparation of pharmaceutical compositions having delayed release properties upon intramuscular injection.
    Type: Application
    Filed: January 31, 2017
    Publication date: February 14, 2019
    Applicant: Hexal AG
    Inventors: Max BORN, Christoph LANGES, Hannes LENGAUER
  • Publication number: 20180282336
    Abstract: The present invention refers to the synthesis and intermediates of substituted bicyclic compounds, which are used as a masked form of acrylamides and in particular refers to the synthesis of the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib) and its synthesis intermediates.
    Type: Application
    Filed: October 29, 2015
    Publication date: October 4, 2018
    Applicant: Sandoz AG
    Inventors: Wolfgang Felzmann, Stefanie Brunner, Hannes Lengauer
  • Publication number: 20180193351
    Abstract: The present invention relates to crystalline form C of avibactam sodium and to a process for its preparation. The invention also concerns a pharmaceutical composition comprising form C and one or more antibacterial agents, wherein at least one antibacterial agent is a beta-lactam antibiotic. The pharmaceutical composition of the present invention can be used as medicament, in particular for treatment and/or prevention of bacterial infections.
    Type: Application
    Filed: August 9, 2016
    Publication date: July 12, 2018
    Applicant: Sandoz AG
    Inventors: Andreas Hotter, Verena Adamer, Hannes Lengauer
  • Publication number: 20170369475
    Abstract: The present invention relates to a hydrate of flibanserin, a process for its preparation and to a pharmaceutical composition comprising the hydrate. The invention further relates to the use of said pharmaceutical composition as a medicament in particular for the treatment of hypoactive sexual desire disorder (HSDD).
    Type: Application
    Filed: June 23, 2016
    Publication date: December 28, 2017
    Applicant: Sandoz AG
    Inventors: Andreas Hotter, Hannes Lengauer, Gerhard Widschwenter
  • Publication number: 20170166570
    Abstract: The present invention relates to the preparation of compounds, in particular to the preparation of compounds which may be used as intermediates for the preparation of antibiotics, preferably carbapenem antibiotics, more preferably ertapenem, and salts thereof.
    Type: Application
    Filed: January 17, 2017
    Publication date: June 15, 2017
    Applicant: Sandoz AG
    Inventors: Hannes Lengauer, Birgit Endl, Wolfgang Felzmann
  • Patent number: 9546171
    Abstract: The present invention relates to the preparation of compounds, in particular to the preparation of compounds which may be used as intermediates for the preparation of antibiotics, preferably carbapenem antibiotics, more preferably ertapenem, and salts thereof.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: January 17, 2017
    Assignee: Sandoz AG
    Inventors: Hannes Lengauer, Birgit Endl, Wolfgang Felzmann
  • Publication number: 20150274732
    Abstract: The present invention relates to the preparation of compounds, in particular to the preparation of compounds which may be used as intermediates for the preparation of antibiotics, preferably carbapenem antibiotics, more preferably ertapenem, and salts thereof.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 1, 2015
    Applicant: Sandoz AG
    Inventors: Hannes Lengauer, Birgit Endl, Wolfgang Felzmann
  • Patent number: 8008490
    Abstract: The present invention relates to novel polymorphic forms of aripiprazole and processes for producing them. It further relates to pharmaceutical compositions comprising the novel forms and to the use of the novel forms in the treatment of schizophrenia.
    Type: Grant
    Filed: January 27, 2006
    Date of Patent: August 30, 2011
    Assignee: Sandoz AG
    Inventors: Josef Wieser, Hannes Lengauer, Doris Braun, Ulrich Griesser, Richard Tessadri
  • Publication number: 20100204470
    Abstract: The present invention provides a new method for preparation and crystallization of hydrochlorides, hydrobromides or hydroiodides of pharmaceutical compounds or their intermediates in which the base or its acid addition salt is reacted in a solvent with a Trialkylsilylhalogenide.
    Type: Application
    Filed: June 25, 2007
    Publication date: August 12, 2010
    Inventors: Josef Wieser, Hannes Lengauer, Elfriede Klingler, Arthur Pichler, Hubert Sturm
  • Publication number: 20080132518
    Abstract: The present invention relates to novel polymorphic forms of aripiprazole and processes for producing them. It further relates to pharmaceutical compositions comprising the novel forms and to the use of the novel forms in the treatment of schizophrenia.
    Type: Application
    Filed: January 27, 2006
    Publication date: June 5, 2008
    Applicant: SANDOZ AG
    Inventors: Josef Wieser, Hannes Lengauer, Doris Braun, Ulrich Griesser, Richard Tessadri